⚕️Founder of Patients VIP 🔬Get Healthcare at no cost and paid along the way through studies ⚡️ Sign up for new clinical trial opportunities👇
Joined May 2024
- Tweets48
- Following8
- Followers32
- Likes698
Blind for 20 years, Brent Chapman now sees 20/30. Dr. Greg Moloney's team in Vancouver fitted a lens into his own canine tooth, grew it in his cheek, then moved it into his eye. Only for patients with no other options.
Joseph Minkowitz retweeted
This is literally unbelievable…
An 80-year-old with severe Alzheimer’s just REGAINED her memory, emotions, ability to speak, ability to walk, AND bladder control after ONE psilocybin dose.
No Alzheimer’s drug has EVER done anything remotely close to this.
Donor islet cells are regulated as a drug, not an organ, which drives up cost and limits access. The FDA has opened public comment on changing that. Eledon is also seeking clearance for a study aimed at rejection. #Type1Diabetes
A robot called Aletta just got FDA De Novo authorization to run a full blood draw on its own. In a multicenter study, it hit the vein on the first try in 92.7% of people with difficult veins. A clinician still oversees each draw.
A hair growth pill is going viral. Veradermics reported early, consistent results for its investigational oral VDPHL01. I explain what the announcement actually says, and what it doesn't. #ClinicalResearch
A daily pill just cut type 2 diabetes blood sugar by 1.9 points in 26 weeks, with 90% hitting the standard target. No injections, no food timing. Still Phase 2, but a remarkable number. astrazeneca.com/media-centre…
Type 1 diabetes: all 12 patients went fully off insulin after an islet transplant with tegoprubart, a new immune drug that doesn't poison the donated cells like the old standard did. 5.4% avg blood sugar, zero rejections. Only 12 people, but 12 for 12.
A monthly shot now prevents migraines in kids as young as 6. The SPACE trial: 47% had migraines cut in half. FDA-approved Aug 2025. Only studied in kids 45+ kg. doi.org/10.1056/nejmoa250454…
Obesity drug retatrutide: 28% avg weight loss (70 lbs) in 2,339 people over 80 weeks, the most any drug has ever achieved. Also cut knee pain 73% and sleep apnea 60%. Still Phase 3, not yet approved.
Obesity pill alert: AstraZeneca's elecoglipron hit 11.8% weight loss in 36 weeks (Phase 2, n=310), with no plateau. 88.8% lost 5%+. Oral GLP-1, no injections. Phase 3 next. doi.org/10.1016/S0140-6736(2…
ADHD drug centanafadine hits dopamine, norepinephrine AND serotonin, a first. 16.3 vs 10.8 point symptom improvement at 6 weeks. Not an amphetamine, low abuse risk. FDA decides July 24, 2026. pharmacytimes.com/view/centa…
Crohn's fistula patients waited 20 years for this. Guselkumab hit 28% true remission (inside + out on MRI). First Phase 3 win in two decades.
Pancreatic cancer after first-line chemo fails has almost no good options. Daraxonrasib just nearly doubled survival in Phase 3: 13.2 vs 6.7 months, 60% lower death risk, and fewer side effects. Real numbers. doi.org/10.1056/NEJMoa260555…
Polymyalgia Rheumatica: the largest trial ever run for PMR just doubled remission rates. 41% on Cosentyx achieved lasting remission at 52 weeks vs 20% on steroids alone (381 patients, 27 countries). Regulatory filings now in the US, EU + Japan.
Ozempic found INSIDE joint fluid for the first time. 12,125 rheumatoid arthritis patients on semaglutide had less pain, stiffness, and swelling at 30 days, 90 days, and 1 year. It may act directly in the joint, not just via weight loss.
Lupus CAR-T trial: 100% response rate in all 18 patients. 78% low disease activity. 50% full remission. Off-the-shelf, outpatient-compatible. Phase 1/2, small sample, but stunning early data. rheumnow.com/news/eular-2026…
Narcolepsy type 2 just got its first Phase 2 win. Alixorexton hit both wakefulness goals in 93 patients by replacing the brain's missing wake signal. Type 1 trial: 3 min awake at baseline to 24-28 min. Phase 3 starting now.
Refractory rheumatoid arthritis: 71% major response, 0 relapses, 0 cytokine release syndrome with off-the-shelf NK cell therapy. Only 13 patients so far, but FDA fast-tracked it and Phase 3 is coming.
MS patients told they were "too advanced" for treatment finally have data. Ocrevus cut disability progression by 30% and hand function loss by 41% in wheelchair users. Largest PPMS trial ever. thelancet.com/journals/lance…
Heart failure patients had lab-grown muscle patches sutured onto their failing hearts. Ejection fraction up 6.9%, wall thickness up 4.5 mm, quality of life +15 pts. Phase 1-2, no control arm, but the signal is real. doi.org/10.1056/NEJMoa251352…
